X0609 4 2026-08-27 0 0001232524 Jazz Pharmaceuticals plc JAZZ 0001737329 Iannone Robert true 5TH FL, WATERLOO EXCHANGE WATERLOO RD DUBLIN 4 L2 IRELAND 0 1 0 0 EVP, Global Head of R&D & CMO 1 Ordinary Shares 2026-08-27 4 M 0 26116 113.1 A 111223 D Ordinary Shares 2026-08-27 4 M 0 884 113.1 A 112107 D Ordinary Shares 2026-08-27 4 M 0 27584 137.12 A 139691 D Ordinary Shares 2026-08-27 4 M 0 2916 137.12 A 142607 D Ordinary Shares 2026-08-27 4 S 0 18187 247.8573 D 124420 D Ordinary Shares 2026-08-27 4 S 0 11423 248.6664 D 112997 D Ordinary Shares 2026-08-27 4 S 0 18113 250.0178 D 94884 D Ordinary Shares 2026-08-27 4 S 0 19639 250.6032 D 75245 D Ordinary Shares 2026-08-27 4 S 0 9259 251.9499 D 65986 D Ordinary Shares 2026-08-27 4 S 0 300 252.76 D 65686 D Incentive Stock Option (right to buy) 113.1 2026-08-27 4 M 0 884 0.0 D 2030-02-26 Ordinary Shares 884 0 D Incentive Stock Option (right to buy) 137.12 2026-08-27 4 M 0 2916 0.0 D 2029-08-07 Ordinary Shares 2916 0 D Non-Qualified Stock Option (right to buy) 113.1 2026-08-27 4 M 0 26116 0.0 D 2030-02-26 Ordinary Shares 26116 0 D Non-Qualified Stock Option (right to buy) 137.12 2026-08-27 4 M 0 27584 0.0 D 2029-08-07 Ordinary Shares 27584 0 D This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. By: /s/Paz Dizon, as attorney in fact For: Robert Iannone 2026-08-31